Development and optimization of an adenovirus production process

Journal of Gene Medicine

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Kamen, Amine ^a   Henry, Olivier ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adenovirus; Bioreactor; Gene therapy; Process; Production; Purification; Quantitation; Scale up; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN;

BATCH CELL CULTURE; CELL DENSITY; CELL RESPIRATION; CELL STRAIN HEK293; CLINICAL PROTOCOL; FED BATCH CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOLECULAR PROBE; NONHUMAN; ONLINE MONITORING; PERFUSION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SAFETY; SCALE UP; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS PARTICLE; VIRUS PURIFICATION; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BIOREACTOR; GEL CHROMATOGRAPHY; GENE VECTOR; GROWTH, DEVELOPMENT AND AGING; INSTRUMENTATION; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; VIRUS CULTURE;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; BIOREACTORS; CHROMATOGRAPHY, GEL; GENETIC VECTORS; HUMANS; MICROBIOLOGICAL TECHNIQUES; VIRUS CULTIVATION;

EID: 3042704538     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.503     Document Type: Review

References (39)

1. Wiley web site: www.wiley.co.uk/genetherapy/clinical/(October 2002).
2. Trapnell BC. Adenoviral vectors for gene transfer. Adv Drug Deliv Rev 1993; 12: 185-199.
3. Wickham TJ. Targeting adenovirus. Millennium review article. Gene Ther 2000; 7: 110-114.
4. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000; 7: 1707-1714.
5. Vorberg SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002; 7: 46-59.
6. Morsy MA, Caskey CT. Expanded-capacity adenoviral vectors - the helper-dependent vectors. Mol Med Today 1999; 5: 18-24.
7. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-2604.
8. Oualikene W, Lamoureux L, Weber JM, et al. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutant for vaccination and gene therapy. Hum Gene Ther 2000; 11: 1341-1353.
9. Nadeau I, Kamen A. Production of adenovirus vector for gene therapy. Adv Biotechnol 2002; 5245: 1-14.
10. Xie L, Pilbrough W, Metallo C, et al. Adenovirus process development and scale-up for HIV vaccines production in cell culture engineering VIII, April 1-6, 2002, Snowmass, Colorado.
11. Côté J, Bourget L, Garnier A, et al. Green fluorescent protein as reporter gene for adenovirus production in serum-free 293SF suspension culture. Biotechnol Prog 1997; 13 709-714.
12. Côté J, Garnier A, Massie B, et al. Serum-free production of recombinant proteins and adenoviral vectors by 293SF cells. Biotechnol Bioeng 1998; 59: 567-575.
13. Garnier A, Cote J, Nadeau I, et al. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 1994; 15: 145-155.
14. Gilbert PA, Garnier A, Jacob D, et al. On-line measurement of GFP fluorescence for the monitoring of recombinant adenovirus production. Biotech Lett 2000; 22: 561-567.
15. Klyushnichenko V, Bernier A, Kamen A, et al. Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J Chromatogr B 2001; 755: 27-36.
16. Nadeau I, Garnier A, Côté J, et al. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnol Bioeng 1996; 51: 613-623.
17. Nadeau I., Jacob D, Perrier M, et al. 293SF metabolic flux analysis during cell growth and infection with an adenoviral vector. Biotechnol Prog 2000; 16: 872-884.
18. Nadeau I, Gilbert PA, Jacob D, et al. Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol Bioeng 2002; 77: 91-104.
19. Transfiguracion J, Bernier A, Arcand N, et al. Validation of a high-performance liquid chromatography assay for the quantification of adenovirus type 5 particles. J Chromatogr B 2001; 761: 187-194.
20. Gilbert R, Nalbantoglu J, Petrof BJ, et al. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 1999; 10: 1299-1310.
21. Graham FL. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
22. Shabram PW, Giroux DD, Goudreau AM, et al. Analytical anion exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997; 8: 453-465.
23. Kamen A, Bédard C, Tom R, et al. On-line monitoring of respiration in healthy and recombinant-baculovirus infected cell bioreactor cultures. Biotechnol Bioeng 1996; 50: 36-48.
24. Zeiser A, Bédard C, Voyer R, et al. On-line monitoring of the progress of infection in Sf-9 insect cell cultures using relative permittivity measurements. Biotechnol Bioeng 1999; 60: 122-127.
25. Hutchins B. Development of a reference material for characterizing adenovirus vector. Bioprocess J 2002; 1: 25-28.
26. Maizel JV, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A and 12. Virology 1968; 36: 115-125.
27. Murakami P, McCaman MT. Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal Biochem 1999; 274: 283-288.
28. Lehmberg E, Traina JA, Chakel JA, et al. Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. J Chromatogr. B 1999; 732: 411-423.
29. Nyberg-Hoffman C, Shabram P, Li W, et al. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
30. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
31. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72: 2022-2032.
32. Hehir KM, Armentano D, Cardoza LM, et al. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol 1996; 70: 8459-8467.
33. Zhu J, Grace M, Casale J, et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum Gene Ther 1999; 10: 113-121.
34. Roitsch C, Achstetter T, Benchaibi M, et al. Characterization and quality control of recombinant adenovirus vectors for gene therapy. J Chromatogr B 2001; 752: 263-280.
35. Johnson M, Lanthier S, Massie B, et al. Use of the Centritech lab centrifuge for perfusion culture of hybridoma cells in protein-free medium. Biotechnol Prog 1996; 12: 855-864.
36. Huygues BG, Liu X, Sutjipto S. Purification of type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995; 6: 1403-1416.
37. Arcand N, Bernier A, Transfiguracion J, et al. Adenovirus type 5 (Ad5) chromatographic purification process at 20L scale. Bioprocess J 2003; 2: 72-75.
38. Green AP, Huang JJ, Scott MO, et al. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 2002; 13: 1921-1934.
39. Hoganson DK, Ma JC, Asato L, et al. Development of a stable adenoviral vector formulation. Bioprocess J 2002; 1: 43-48.